3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
59
Neoplasms
6
Neoplasm Metastasis
5
Melanoma
5
Carcinoma, Non-Small-Cell Lung
5
Colorectal Neoplasms
4
Ovarian Neoplasms
3
Neoplasms by Site
3
Hereditary Sensory and Autonomic Neuropathies
3
Endometrial Neoplasms
3
Breast Diseases
3
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Neuroblastoma
2
Multiple Endocrine Neoplasia Type 1
2
Lymphoma
2
Lung Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Triple Negative Breast Neoplasms
1
Teratoma
1
Stomach Neoplasms
1
Solid Tumors Harboring a BRAF V600 Mutation
1
Solid Tumors
1
Rhabdomyosarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Osteitis Deformans
1
Neoplasms, Germ Cell and Embryonal
1
Interventions
ribociclib
1
palbociclib
1
abemaciclib
1
AZD9833
1
AZD9496
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
ER+ HER2- Advanced Breast Cancer
×
ribociclib
×
Clear all
NCT06188520
2026-05-11
CYCAD-1
AstraZeneca
Phase 1/2
Recruiting
564 enrolled